1. Home
  2. PKG vs BIIB Comparison

PKG vs BIIB Comparison

Compare PKG & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Packaging Corporation of America

PKG

Packaging Corporation of America

HOLD

Current Price

$198.35

Market Cap

17.8B

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$181.52

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PKG
BIIB
Founded
1867
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Containers/Packaging
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.8B
24.2B
IPO Year
2000
1991

Fundamental Metrics

Financial Performance
Metric
PKG
BIIB
Price
$198.35
$181.52
Analyst Decision
Buy
Buy
Analyst Count
7
23
Target Price
$233.43
$176.48
AVG Volume (30 Days)
739.3K
1.9M
Earning Date
01-27-2026
10-30-2025
Dividend Yield
2.52%
N/A
EPS Growth
15.38
N/A
EPS
9.90
10.97
Revenue
$8,771,800,000.00
$10,065,900,000.00
Revenue This Year
$9.43
$3.61
Revenue Next Year
$13.27
N/A
P/E Ratio
$20.05
$16.52
Revenue Growth
7.30
4.77
52 Week Low
$172.72
$110.04
52 Week High
$245.87
$185.17

Technical Indicators

Market Signals
Indicator
PKG
BIIB
Relative Strength Index (RSI) 47.80 72.92
Support Level $191.65 $174.53
Resistance Level $205.68 $182.94
Average True Range (ATR) 4.48 5.22
MACD 0.28 0.25
Stochastic Oscillator 48.31 83.54

Price Performance

Historical Comparison
PKG
BIIB

About PKG Packaging Corporation of America

Packaging Corp. of America is the third-largest containerboard and corrugated packaging manufacturer in the United States. It produces over 5 million tons of containerboard annually. The company's share of the domestic containerboard market is roughly 10%. PCA differentiates itself from larger competitors by focusing on smaller customers and operating with a high degree of flexibility.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: